Glucagon-like peptide-1 (GLP-1) receptor agonists treat type 2 diabetes (T2D) and obesity through mechanisms including inhibition of glucagon secretion, food intake, and gastric emptying, as well as stimulation of insulin secretion[1]. The gene discussed is INS; the disease is Obesity.